Lluís Puig1, Jose G Ruiz de Morales2, Esteban Dauden3, José Luís Andreu4, Ricard Cervera5, Alfredo Adán6, Sara Marsal7, Carina Escobar8, Joaquín Hinojosa9, Javier Palau10, Antonio Arraiza11, Paloma Casado12, María Codesido12, César Pascual13, Roberto Saldaña14, Ángel Gil15. 1. Servicio de Dermatología. Hospital de la Santa Creu i Sant Pau. Barcelona. España. 2. Servicio de Inmunología. Complejo Hospitalario Universitario de León. León. España. 3. Servicio de Dermatología. Hospital Universitario de La Princesa. Madrid. España. 4. Servicio de Reumatología, Hospital Universitario Puerta de Hierro-Majadahonda. Madrid. España. 5. Servicio de Enfermedades Autoinmunes. Hospital Clínic de Barcelona. Barcelona. España. 6. Instituto de Oftalmología. Hospital Clinic de Barcelona. Barcelona. España. 7. Grupo de Investigación de Reumatología. Institut de Recerca. Hospital Universitari Vall d'Hebron. Barcelona. España. 8. UNIMID (Asociación de Personas con Enfermedades Crónicas Inflamatorias Inmunomediadas). Madrid. España. 9. Servicio de Medicina Digestiva. Hospital de Manises. Valencia. España. 10. Departamento de Salud de La Ribera. Valencia. España. 11. Asistencia Sanitaria. Dirección General. Osakidetza. Vitoria-Gasteiz. España. 12. Calidad y Cohesión. Ministerio de Sanidad, Servicios Sociales e Igualdad. Madrid. España. 13. Hospital Nisa Pardo de Aravaca. Madrid. España. 14. Confederación ACCU (Confederación de afectados por Crohn y Colitis Ulcerosa). Madrid. España. 15. Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain.
Abstract
OBJECTIVE: Immune-mediated inflammatory diseases (IMID) are chronic and highly disabling diseases that share inflammatory sequences and immunological dysregulations. Considered as a disease in itself, the prevalence of IMID is virtually unknown. The aim of this study was to assess the prevalence of 10 selected UDI, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, hidradenitis suppurativa, sarcoidosis and uveitis in Spain. METHODS: cross-sectional epidemiological study of point prevalence was made. This study was carried out through a series of computerized interviews in households chosen at random in 17 autonomous communities in Spain. A structured questionnaire was used to determine the frequency of diagnosis and the concurrence of 10 IMID in the respondents and other individuals belonging to the same family nucleus. The point prevalence estimates were used and compared with the objective of determining the frequency of IMID by age, sex and communities. The data were processed using Excel 2016 (Microsoft, Redmond, WA, USA) and the SPSS V.019 system (IBM Corp. Armonk, NY, USA) for statistical analysis using the usual statistical tests in this type of studies. RESULTS: Of the 7,980 respondents, 510 were diagnosed with an IMID, representing a cross-sectional study of 6.39% (95% CI: 6.02-6.76). One, two, three or more members of the family were affected in 87.2%, 7.8% and 5% of positive relatives in IMID, respectively. The most recurrent diseases were psoriasis (2.69% [95% CI: 2.32-3.06]) and rheumatic arthritis (1.07% [95% CI: 0.70-1.44]). There were differences in prevalence due to sex (p = 0.004) and age (p = 0.000). No significant differences were identified related to geographic location (p = 0.819). Attendance of at least 2 IMID was reported in 8.9% of respondents. CONCLUSIONS: The overall prevalence was of the IMID studied was 6.39%, psoriasis being the most frequent with 2.69%. This study constitutes an initial step to consider IMID as an independent disease within the health system..
OBJECTIVE: Immune-mediated inflammatory diseases (IMID) are chronic and highly disabling diseases that share inflammatory sequences and immunological dysregulations. Considered as a disease in itself, the prevalence of IMID is virtually unknown. The aim of this study was to assess the prevalence of 10 selected UDI, including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, hidradenitis suppurativa, sarcoidosis and uveitis in Spain. METHODS: cross-sectional epidemiological study of point prevalence was made. This study was carried out through a series of computerized interviews in households chosen at random in 17 autonomous communities in Spain. A structured questionnaire was used to determine the frequency of diagnosis and the concurrence of 10 IMID in the respondents and other individuals belonging to the same family nucleus. The point prevalence estimates were used and compared with the objective of determining the frequency of IMID by age, sex and communities. The data were processed using Excel 2016 (Microsoft, Redmond, WA, USA) and the SPSS V.019 system (IBM Corp. Armonk, NY, USA) for statistical analysis using the usual statistical tests in this type of studies. RESULTS: Of the 7,980 respondents, 510 were diagnosed with an IMID, representing a cross-sectional study of 6.39% (95% CI: 6.02-6.76). One, two, three or more members of the family were affected in 87.2%, 7.8% and 5% of positive relatives in IMID, respectively. The most recurrent diseases were psoriasis (2.69% [95% CI: 2.32-3.06]) and rheumatic arthritis (1.07% [95% CI: 0.70-1.44]). There were differences in prevalence due to sex (p = 0.004) and age (p = 0.000). No significant differences were identified related to geographic location (p = 0.819). Attendance of at least 2 IMID was reported in 8.9% of respondents. CONCLUSIONS: The overall prevalence was of the IMID studied was 6.39%, psoriasis being the most frequent with 2.69%. This study constitutes an initial step to consider IMID as an independent disease within the health system..
Authors: Cristina García-Serrano; Glòria Mirada; Josep R Marsal; Marta Ortega; Joaquim Sol; Rubén Solano; Eva M Artigues; Pepi Estany Journal: BMC Public Health Date: 2020-05-19 Impact factor: 3.295
Authors: Rosa Romero-Jimenez; Vicente Escudero-Vilaplana; Esther Chamorro-de-Vega; Arantza Ais-Larisgoitia; Elena Lobato-Matilla; Beatriz Somoza-Fernández; Paula Ruiz-Briones; Carlos González; Ofelia Baniandrés; Luis Menchén; Carmen Lobo-Rodríguez; Ana Herranz; María Sanjurjo Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786
Authors: Miguel A Ortega; Cielo García-Montero; Oscar Fraile-Martinez; Miguel Angel Alvarez-Mon; Ana Maria Gómez-Lahoz; Guillermo Lahera; Jorge Monserrat; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Álvarez-Mon Journal: Biology (Basel) Date: 2022-06-28